Gilead Sciences stock (US3755581036): Q1 earnings beat, buybacks and HIV milestone

Gilead Sciences reported Q1 2026 revenue of $7.0 billion, up 4% year-over-year, with EPS of $2.03 beating estimates. The company completed a $4.57 billion share buyback and secured FDA priority review for a new HIV regimen.

Gilead Sciences released its first-quarter 2026 results on May 7, 2026, posting revenue of $7.0 billion, a 4% increase from the prior year, and earnings per share of $2.03, surpassing analyst expectations of $1.61. Total product sales rose 5% to $6.9 billion, driven by strong HIV franchise growth. The company also completed a multi-year $4.57 billion share repurchase program and filed a $6.51 billion shelf registration, according to Simply Wall St as of 05/11/2026 and moomoo as of 05/11/2026.

The HIV portfolio showed significant demand improvement, with Gilead raising its full-year outlook. Additionally, the FDA accepted the New Drug Application for a once-daily bictegravir/lenacapavir HIV regimen under priority review, highlighting pipeline progress amid a lower full-year earnings forecast due to acquisition charges.

As of: 11.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gilead Sciences
• Sector/industry: Biopharmaceuticals
• Headquarters/country: United States
• Core markets: US, Europe, HIV and oncology
• Key revenue drivers: HIV treatments, antivirals
• Home exchange/listing venue: Nasdaq (GILD)
• Trading currency: USD

Gilead Sciences: core business model

Gilead Sciences focuses on developing and commercializing therapies for life-threatening diseases, with a strong emphasis on virology, oncology, and inflammation. The company markets leading HIV treatments like Biktarvy, which remains a cornerstone of its revenue. Headquartered in Foster City, California, Gilead operates globally, with significant US market exposure relevant to American investors tracking biotech leaders.

Its business model relies on innovation in antivirals and targeted therapies, supported by a robust pipeline. Gilead has expanded through acquisitions, bolstering its oncology portfolio with drugs like Trodelvy. For Q1 2026, HIV sales drove growth, per the earnings release.

Main revenue and product drivers for Gilead Sciences

HIV remains Gilead's largest revenue driver, with Q1 2026 product sales up 5% to $6.9 billion, fueled by improved demand trends for Biktarvy and other regimens, as reported by ValueTheMarkets as of 05/11/2026. Oncology and liver disease treatments contribute meaningfully, with the US accounting for the majority of sales.

Recent milestones include the FDA priority review for bictegravir/lenacapavir, potentially adding to the HIV portfolio. The completed $4.57 billion buyback signals confidence in valuation, returning capital to shareholders.

Industry trends and competitive position

The biopharma sector faces patent cliffs and pricing pressures, but Gilead's entrenched HIV market share provides stability. Competitors like Pfizer and GSK vie in antivirals, yet Gilead's once-daily regimens maintain leadership. US investors benefit from Nasdaq listing and exposure to domestic healthcare spending.

Why Gilead Sciences matters for US investors

Listed on Nasdaq as GILD, Gilead offers US investors access to a defensive biotech play with steady HIV cash flows amid volatile markets. Its US headquarters and heavy reliance on American prescriptions tie performance to the domestic economy and FDA decisions.

Conclusion

Gilead Sciences delivered solid Q1 2026 results with revenue growth and HIV strength, complemented by buybacks and pipeline advances. While acquisition charges temper full-year earnings, the core business executes well. Investors monitor upcoming catalysts like FDA reviews and sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.